A potent synthetic GHRP with decades of research history and one of the strongest GH stimulation profiles.
GHRP-2 (also known as pralmorelin) is a synthetic hexapeptide that acts as a ghrelin mimetic, stimulating GH release from the pituitary. It was among the first GHRPs extensively studied in clinical research and has a well-characterized pharmacological profile spanning decades of research.
GHRP-2 produces strong GH release but also increases cortisol and ACTH more than ipamorelin, though less than GHRP-6. It has been used in diagnostic testing of GH axis function — a pralmorelin test is an established provocation test for GH deficiency in some countries.
In Japan, pralmorelin was approved as a diagnostic test for growth hormone secretion. This rare approval status (even if limited to diagnostics) distinguishes it from many research peptides with no regulatory recognition.
Extensive clinical research demonstrates GH stimulation across age groups. Head-to-head studies with GHRP-6 show similar efficacy with somewhat less appetite stimulation. Combined with GHRH analogs, GHRP-2 produces synergistic GH release.
Diagnostic use studies have established safe short-term administration profiles. Long-term therapeutic use has less clinical documentation.
📚 Key Reference: PMID: 8788520 (GHRP-2 clinical study)
Cortisol and prolactin elevation occur. Appetite stimulation (milder than GHRP-6). Injection site reactions. Headache. Water retention. Monitor IGF-1 with extended use. Consult your provider.
Not FDA-approved for therapeutic use in the US. Approved for diagnostic use in Japan (pralmorelin). Research chemical status in most jurisdictions.